← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema
lanadelumab
B06AC05
Forms & Strengths
- Subcutaneous solution: 300 mg/2 mL single-dose vial
Adult Dosing
- Initial dose: 300 mg subcutaneously every 2 weeks
- Dosing frequency reduction: 300 mg every 4 weeks may be considered if the patient is well-controlled for more than 6 months
Pediatric Dosing
- Pediatric patients 12 years and older: 300 mg subcutaneously every 2 weeks
- Pediatric patients 2 to <12 years: 150 mg subcutaneously every 2 weeks (weight-adjusted dosing may apply per local labeling)
Indications
- Prophylaxis to prevent acute attacks of hereditary angioedema (HAE) in patients 2 years of age and older
Mechanism of Action
- Fully human monoclonal IgG1 kappa antibody that specifically binds to and inhibits plasma kallikrein
- Prevents the proteolytic cleavage of high-molecular-weight kininogen to bradykinin, thereby reducing vascular permeability, vasodilation, and pain associated with HAE attacks
Contraindications
- History of severe hypersensitivity reaction to lanadelumab or its excipients
Adverse Reactions
- Injection site reactions (pain, erythema, bruising)
- Upper respiratory tract infections
- Headache
- Rash
- Myalgia
- Dizziness
- Elevated transaminases
Drug Interactions
- Formal clinical drug interaction studies have not been performed
- Concomitant use with acute HAE treatments (e.g., C1 esterase inhibitor, icatibant) is permissible for breakthrough attacks
- Theoretical interaction with other anticoagulants or antifibrinolytic agents (though unlikely to alter systemic pharmacokinetics significantly)
Curated Content: Needs Vetting Before Put to Clinical Use